Cervical cancer: Difference between revisions

From Citizendium
Jump to navigation Jump to search
imported>Robert Badgett
No edit summary
imported>Robert Badgett
m (→‎Effectiveness of screening: Fixed bad PMID in reference)
Line 32: Line 32:
In a [[randomized controlled trial]], the addition of Human papillomavirus testing to screening for cervical cancer "reduces the incidence of grade 2 or 3 cervical intraepithelial neoplasia or cancer detected by subsequent screening examinations."<ref name="pmid17942871">{{cite journal |author=Mayrand MH, Duarte-Franco E, Rodrigues I, ''et al'' |title=Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer |journal=N. Engl. J. Med. |volume=357 |issue=16 |pages=1579–88 |year=2007 |pmid=17942871 |doi=10.1056/NEJMoa071430|url=http://content.nejm.org/cgi/content/full/357/16/1579}}</ref>
In a [[randomized controlled trial]], the addition of Human papillomavirus testing to screening for cervical cancer "reduces the incidence of grade 2 or 3 cervical intraepithelial neoplasia or cancer detected by subsequent screening examinations."<ref name="pmid17942871">{{cite journal |author=Mayrand MH, Duarte-Franco E, Rodrigues I, ''et al'' |title=Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer |journal=N. Engl. J. Med. |volume=357 |issue=16 |pages=1579–88 |year=2007 |pmid=17942871 |doi=10.1056/NEJMoa071430|url=http://content.nejm.org/cgi/content/full/357/16/1579}}</ref>


In another [[randomized controlled trial]], the addition of Human papillomavirus testing to screening for cervical cancer led to  earlier detection of CIN3+ lesions.<ref name="pmid17919718">{{cite journal |author=Bulkmans NW, Berkhof J, Rozendaal L, ''et al'' |title=Human papillomavirus DNA testing for the detection of cervical intraepithelial neoplasia grade 3 and cancer: 5-year follow-up of a randomised controlled implementation trial |journal=Lancet |volume=370 |issue=9601 |pages=1764–72 |year=2007 |pmid=17919718 |doi=10.1016/S0140-6736(07)61450-0}}</ref>
In another [[randomized controlled trial]], the addition of Human papillomavirus testing to screening for cervical cancer led to  earlier detection of CIN3+ lesions.<ref name="pmid17942872">{{cite journal |author=Naucler P, Ryd W, Törnberg S, ''et al'' |title=Human papillomavirus and Papanicolaou tests to screen for cervical cancer |journal=N. Engl. J. Med. |volume=357 |issue=16 |pages=1589–97 |year=2007 |pmid=17942872 |doi=10.1056/NEJMoa073204 |url=http://content.nejm.org/cgi/pmidlookup?view=short&pmid=17942872&promo=ONFLNS19}}</ref>
 
 


==References==
==References==
<references/>
<references/>

Revision as of 23:59, 10 March 2008

This article is a stub and thus not approved.
Main Article
Discussion
Related Articles  [?]
Bibliography  [?]
External Links  [?]
Citable Version  [?]
 
This editable Main Article is under development and subject to a disclaimer.

Screening

Accuracy of screening tests

Papanicolaou smear

A systematic review of available studies found the follow results.[1]

Ability to detect ASCUS or worse.[1]
ASCUS or worse High grade or worse
sensitivity specificity sensitivity specificity
Conventional method 88% 71% 55% 97%
Liquid-based thin prep 88% 71% 57% 97%

A more recent study of the convention method reported very similar results:[2]

Human papillomavirus testing

Combined testing

If either the Papanicolaou smear or Human papillomavirus testing are abnormal:

Effectiveness of screening

In a randomized controlled trial, the addition of Human papillomavirus testing to screening for cervical cancer "reduces the incidence of grade 2 or 3 cervical intraepithelial neoplasia or cancer detected by subsequent screening examinations."[2]

In another randomized controlled trial, the addition of Human papillomavirus testing to screening for cervical cancer led to earlier detection of CIN3+ lesions.[3]

References

  1. 1.0 1.1 Arbyn M, Bergeron C, Klinkhamer P, Martin-Hirsch P, Siebers AG, Bulten J (2008). "Liquid Compared With Conventional Cervical Cytology: A Systematic Review and Meta-analysis". Obstet Gynecol 111 (1): 167–177. DOI:10.1097/01.AOG.0000296488.85807.b3. PMID 18165406. Research Blogging.
  2. 2.0 2.1 2.2 2.3 2.4 2.5 Mayrand MH, Duarte-Franco E, Rodrigues I, et al (2007). "Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer". N. Engl. J. Med. 357 (16): 1579–88. DOI:10.1056/NEJMoa071430. PMID 17942871. Research Blogging.
  3. Naucler P, Ryd W, Törnberg S, et al (2007). "Human papillomavirus and Papanicolaou tests to screen for cervical cancer". N. Engl. J. Med. 357 (16): 1589–97. DOI:10.1056/NEJMoa073204. PMID 17942872. Research Blogging.